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Abstract
Background: Randomised control trials and genetic analyses have demonstrated that vitamin D or 25-hydroxyvitamin
D (25[OH]D) levels may not play a causal role in the development of cardiovascular disease. However, it is
unclear if 25(OH)D is causally associated with cause-specific vascular disease and lipids. Therefore, we examined
the causal association of 25(OH)D with myocardial infarction, stroke, ischaemic heart disease, ischaemic stroke,
subarachnoid haemorrhage, intracerebral haemorrhage, and lipid levels among both Chinese and Europeans.
Methods: We used a Mendelian randomisation (MR) design in the China Kadoorie Biobank, the Copenhagen
City Heart Study, and the Copenhagen General Population Study. The 25(OH)D-related genetic variants in the
CYP2R1 and DCHR7 genes were genotyped in 99,012 Chinese adults and 106,911 Danish adults.
Results: In Chinese adults, plasma 25(OH)D levels were not significantly associated with cause-specific vascular disease
or mortality, with the exception of intracerebral haemorrhage (HR, 1.09 [95% CI, 1.01,1.18] per 25 nmol/L higher plasma
25(OH)D). In Europeans, plasma 25(OH)D levels were inversely associated with all types of vascular diseases and
mortality. However, MR analysis did not demonstrate causal associations of genetically increased 25(OH)D levels with
cause-specific vascular diseases, or mortality in both Chinese and European adults. In addition, each 25 nmol/L higher
25(OH)D was observationally associated with lower total cholesterol and low-density lipoprotein cholesterol levels, but
higher high-density lipoprotein cholesterol levels. Likewise, MR analysis showed that 25(OH)D levels were not causally
associated with lipids in both Chinese and European adults after Bonferroni correction.
Conclusions: We found no evidence to support that genetically increased 25(OH)D was associated with a lower risk
of ischaemic stroke, intracerebral haemorrhage, subarachnoid haemorrhage, and lipid levels in both Chinese and
European adults. These results suggest that the inverse associations of vitamin D with vascular disease could be the
result of confounding.
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Background
Observational studies have shown that low plasma levels of
vitamin D are associated with higher risks of cardiovascular
disease (CVD) [1–3] and mortality from CVD, cancer, and
all causes [2, 4, 5] in European populations. However,
randomised intervention trials (RCTs) of vitamin D3
(cholecalciferol) supplementation have not clearly demon-
strated any protective effect on CVD [6–9] or all-cause
mortality [10, 11]. Findings from Mendelian randomisation
(MR) analysis also did not indicate causal association of 25-
hydroxyvitamin D (25[OH]D), usually used to assess vita-
min D status, with increased risk of ischaemic heart disease,
myocardial infarction [12], and cardiovascular mortality
[13], but showed a possible effect on all-cause and cancer
mortality in Europeans [13].
No study has evaluated these associations in the Chinese
population, while two studies examined risk of diabetes
[14, 15]. Importantly, the causal associations between
25(OH)D and cause-specific vascular disease such as
stroke, ischaemic stroke, intracerebral haemorrhage,
subarachnoid haemorrhage, and lipid levels have not been
examined among European and Chinese adults. Whether a
high 25(OH)D level is a cause of decreased vascular disease
and mortality or simply a consequence of poor health is
thus unclear. This question has important public health
relevance, as about half of the population have vitamin D
deficiency and regularly take vitamin D supplements [16],
but without proper scientific evidence for any beneficial
effect on many disease outcomes.
With the lack of evidence from intervention trials, a MR
approach, which is regarded as a natural RCT, can poten-
tially be used to make causal inference [17–22]. MR uses
the random assortment of genes during gamete formation
as the natural randomisation process. Therefore, genetic
variants known to influence 25(OH)D concentrations can
be used to examine causality as they partly determine
lifetime exposure to 25(OH)D. Genome-wide association
studies (GWAS) have identified several single nucleotide
polymorphisms (SNPs) that are associated with plasma
25(OH)D concentration in relation to genes involved in
the synthesis of 25(OH)D (DHCR7 and CYP2R1), trans-
port of 25(OH)D via vitamin D-binding protein (GC/
DBP), and metabolism of 25(OH)D (CYP24A1) [23, 24].
The aims of the present study were to test whether
higher 25(OH)D concentrations are observationally as-
sociated with cause-specific vascular diseases, or mortal-
ity and lipids, and whether such associations are causal
among European and Chinese adults.
Methods
Study populations
The China Kadoorie Biobank (CKB) is a prospective
study of 512,891 individuals, aged 30–79 years, who were
enrolled from 5 urban and 5 rural regions in China
during 2004–2008. Previous studies have reported the
details of the study design, participant characteristics,
and survey methods [21]. Information on demographic
data, lifestyle, use of medications, and medical history
were collected by trained health workers by using lap-
top-based questionnaires. Blood pressure, weight, and
height were measured using standard protocols. Body
mass index (BMI) was calculated as body weight in kilo-
grammes divided by height in metres squared. A 10-mL
nonfasting venous blood sample was collected. All par-
ticipants from CKB provided written informed consent.
Ethics approval was obtained from the Peking University
and University of Oxford ethics committees.
The Copenhagen General Population Study (CGPS) is a
prospective cohort study among Danish population
initiated in 2003 [25]. The Copenhagen City Heart Study
(CCHS) was initiated in 1976–1978, and followed up in
1981–1983, 1991–1994, and 2001–2003 [13]. Body weight
and height was measured by standard methods. Blood
pressure was measured in millimetres of mercury with a
sphygmomanometer or an automated digital blood
pressure monitor (Kivex). Leisure time physical activity
was considered in four categories. Smoking information
was classified as pack-years smoked. Alcohol consumption
was based on average weekly consumption of beer, wine,
and liquor. Written informed consent was obtained from
participants. Ethics approval was obtained from Danish
ethical committees.
Biochemical analysis
In CKB, plasma 25(OH)D concentrations were measured
using a Beckman Access-2 immunoassay assay on stored
EDTA plasma samples in 13,565 individuals. The labora-
tory participated in the international Vitamin D Quality
Assessment Scheme (DEQAS) for 25(OH)D and results
had a mean (SD) bias of − 11.8% (7.5) from the target
mean value for the present study. Samples of the CCHS
were stored at − 20 °C (1981–1983), and samples from the
CGPS were stored at − 80 °C (2004–2005). Colorimetric
assays (Mannheim, Boehringer Mannheim, Germany or
Konelab, Finland, Espoo) were used to measure plasma
high-density lipoprotein (HDL) cholesterol and total
cholesterol concentrations. 25(OH)D concentrations were
measured in both serum and plasma using a chemilumin-
escent immunoassay, CLIA (DiaSorin, Stillwater, MN,
USA). The inter- and intra-assay coefficients of variation
were 11% and 10%, respectively.
SNP selection and genotyping
A total of 95,680 individuals from the CKB were
genotyped using a 384-SNP panel (Illumina Golden Gate).
Two synthesis SNPs (CYP2R1-rs10741657 and DHCR7-
rs12785878), one transport SNP (GC/DBP-rs2282679),
and one metabolism SNP (CYP24A1-rs6013897) identified
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for plasma 25(OH)D concentrations in previously GWAS
were included in the SNP panel [20, 21]. The genotyping
concordance was > 99.9% for 2063 pairs of sample
replicates and genotype success rates were 99.9% for each
SNP. In the CGPS, genetic variants for 25(OH)D were
selected based on a reported GWAS [23, 24]. The selected
SNPs either influence synthesis of pre-vitamin D from 7-
dehydrocholesterol in the skin or activate transformation
from vitamin D to 25(OH)D in the liver. TaqMan assays
were used for genotyping for DHCR7 (rs7944926 and
rs11234027) and CYP2R1 (rs10741657 and rs12794714).
Sequencing of randomly selected samples verified the ge-
notypes. All genotype call rates were higher than 99%
complete.
Outcomes
The present study examined major coronary events (fatal
ischaemic heart disease [ICD-10: I20-I25] or nonfatal
myocardial infarction [I21-I23]), major vascular events
[I60 and I64], intracerebral haemorrhage (I61), ischaemic
stroke (I63), and cardiovascular death (I00-I99) as the
primary outcomes in the CKB. Data on disease outcomes
were identified from claims to the national health insur-
ance system and from local chronic disease registries and
disease surveillance point system death registries. Trained
staff members, blinded to the baseline information, used
International Statistical Classification of Diseases and Re-
lated Health Problems (ICD-10) to identify the underlying
causes of death. The deaths were grouped into several cat-
egories: major coronary events [ICD-10: I20-I25], major
vascular events [I60 and I64], ischaemic heart disease
(I20-I25), myocardial infarction [I21-I23], ischaemic stroke
(I63), intracerebral haemorrhage (I61), cancer (C00-C97),
diseases of the respiratory system (J00-J99), infections
(A00-B99), and all other causes.
In the CGPS and CCHS studies, information on diagno-
ses of vascular diseases such as myocardial infarction
(ICD-8: 410; ICD-10: I21-I22) and ischaemic heart disease
(ICD-8: 410 to 414, and ICD-10: I20 to I25) were verified
based on information on diagnoses entered in the national
Danish Patient Registry and hospital admissions. The
national Danish Causes of Death Registry records were
used to identify the causes of death as well as contributing
causes of death [12]. We used underlying causes of death
to classify deaths as due to cardiovascular (ICD-8 390-
458, ICD-10 I00-I99) and cancer (ICD-8 140-209, ICD-10
C00-C97) [13].
Statistical methods
For observational analyses, data were available on 13,565
participants with plasma 25(OH)D levels for observational
analyses, and data were available on 82,464 participants
with all genotypes. Of these, 3397 had data on both
25(OH)D plasma levels and genotypes in CKB. We
included 25,621 participants and 10,271 participants with
plasma 25(OH)D levels in CGPS and CCHS, respectively;
in genetic analyses, we included 106,911 participants with
all genotypes. Of these, 25,332 had both 25(OH)D plasma
levels and genotypes in CGPS. Cox proportional hazard
regression models were used to analysing the relationship
between quartile groups of 25(OH)D levels and risk of
disease. We used Schoenfeld residual test to examine the
proportional hazard assumption. All results (P > 0.05)
showed that the Cox models were acceptable. Multivari-
able Cox regression analyses included age (years), sex
(male or female), smoking status (current smoker), alcohol
intake (current drinker), season, region, systolic blood
pressure (SBP), physical activity (low activity) in the CKB,
and age (years), sex (male or female), season, SBP, physical
activity (low activity), smoking status (current smoker),
and alcohol intake (current drinker) in the CGPS and
CCHS.
Genotype distributions in each study did not differ
from the Hardy-Weinberg equilibrium. Linear regression
was used to examine the per allele effects of each SNP
on plasma 25(OH)D concentrations. Genetic scores were
estimated for the two synthesis SNPs and all four SNPs.
The selected SNPs are not in linkage disequilibrium
(LD). F-statistics were used to estimate the strength of
associations of each SNP with 25(OH)D concentrations,
and F-statistics > 10 were considered strong. We also
used linear regression to assess the relationship of each
SNP with plasma lipids and lipoproteins. All genetic
analyses were adjusted for age at baseline, sex, season,
and region. Analyses of individual SNPs and genetic
scores with outcomes were estimated using Cox propor-
tional hazard regression models. The per allele effects of
each SNP on plasma 25(OH)D concentrations were
expressed as the differences in 25(OH)D concentrations
per copy of the 25(OH)D raising allele.
A two-stage least squared regression model using geno-
type individually and combined allele scores as instruments
was used to examine the influence of a 25 nmol/L increase
in 25(OH)D concentrations on risk of outcomes. We used
the DHCR7/CYP2R1 genetic score as the main instrumen-
tal variable. We calculated causal estimates of genetically
determined hazard ratios (HRs) by using the Wald-type
estimator, which calculates the ratio of the outcome allele
score log hazard ratios to the exposure allele score coeffi-
cient and then exponentiates the ratio to a hazard ratio.
For combination of CVD and lipid data from Asians and
Europeans, meta-analyses were conducted. We assessed
between-study heterogeneity via Cochrane’s Q- and I2-sta-
tistics. A random-effect meta-analysis was used if I2 > 0.25,
otherwise, a fixed-effect model was used [26].
Sensitivity analyses were performed for three-SNP and
four-SNP genetic scores to examine the potential effects
of pleiotropy using the MR-Egger regression method
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[27]. We used SAS version 9.2 and R version 3.01. We
included 20 diseases or cause-specific mortality as
primary outcomes. The threshold of significance was
P < 0.0025 (0.05/20) after Bonferroni correction. P ≤ 0.05
but above the threshold of Bonferroni corrected signifi-
cance was considered as a suggestive causal association.
Results
Characteristics of the CKB, CGPS, and CCHS populations
Among the 82,464 CKB individuals and 106,911 CGPS
individuals in the genetic study, the mean (SD) of age was
51.4 (10.6) and 58.0 (13.1) years, 61% and 55% were
women, and the mean (SD) of BMI was 23.7 (3.4) and 26.1
(4.3) kg/m2, respectively. The overall mean (SD) plasma
25(OH)D concentrations were 63.7 (26.6) nmol/L, 55.3
(26.0) nmol/L, 44.3 (24.1) nmol/L in CKB, CGPS, and
CCHS, respectively (Table 1).
Observational associations
In CKB, plasma 25(OH)D levels were not statistically
associated with major vascular events (multivariable ad-
justed HR per 25 nmol/L higher plasma 25(OH)D, 1.02
[95% CI, 0.98,1.07]), major coronary events (HR, 0.98
[95% CI, 0.89,1.07]), myocardial infarction (HR, 0.99 [95%
CI, 0.89,1.12]), stroke (HR, 1.04 [95% CI, 0.99,1.10]),
ischaemic stroke (HR, 0.99[95% CI, 0.93,1.07]), subarach-
noid haemorrhage (HR, 1.24 [95% CI, 0.83,1.85]), and
ischaemic heart disease (HR, 0.98 [95% CI, 0.89,1.07])
after adjustment for age, sex, smoking status, alcohol
intake, season, region, SBP, and physical activity. However,
each 25 nmol/L higher plasma 25(OH)D concentration
was associated with about a 9% higher risk of intracerebral
haemorrhage (HR, 1.09 [95% CI, 1.01,1.18]) (Table 2).
Likewise, plasma 25(OH)D levels were not significantly as-
sociated with cancer, respiratory diseases, infection-cause
mortality, or all-cause mortality after adjustment for
confounding factors (Table 3). In addition, each 25 nmol/
L higher plasma 25(OH)D concentration was associated
with a 1.52mg/dL higher apoA, 0.04mg/dL higher apoB,
and 0.03mmol/L (1mg/dL) higher HDL cholesterol, but a
0.05mmol/L (2mg/dL) lower total cholesterol, 0.03
mmol/L (1mg/dL) lower LDL cholesterol, and a 0.16
mmol/L (14mg/dL) lower triglycerides (Table 4).
In CGPS and CCHS, each 25 nmol/L higher plasma
25(OH)D concentration was associated with about a 10%
Table 1 Characteristics for all individuals with 25(OH)D measured or with genetic data
Baseline All individuals with 25(OH)D measured Individuals with genetic data
Characteristic CKB CGPS CCHS CKB CGPS
Demographic (n = 13,565) (n = 25,621) (n = 10,271) (n = 82,464) (n = 106,911)
Age (SD), years 53.2 (11.2) 58.5 (13.0) 56.7 (11.9) 51.4 (10.6) 58.0 (13.1)
Women, % 49.2 54.9 55.7 60.5 55
Current smoker, % 47.2 20.5 58.4 36.9 17.1
Current drinker, % 56.8 88.3 69 53.7 89.1
Low physical activity* 18.15 6.8 16.8 18.15 6.2
BMI (SD), kg/m2 23.6 (3.5) 26.1 (4.3) 25.3 (4.2) 23.7 (3.4) 26.1 (4.3)
SBP (SD), mmHg 140.2 (25.9) 141.1 (21.1) 140.5 (21.6) 131.2 (21.3) 141.6 (21.4)
DBP (SD), mmHg 82.2 (14.5) 83.9 (11.4) 85.1 (12.1) 77.8 (11.2) 84.3 (11.5)
Doctor diagnosed prior disease, %
Heart disease 0 6.1 3.5 3 5.8
Stroke 0 1.4 1 1.8 1.3
Hypertension 15.9 60.9 56.1 11.5 60.3
Diabetes 3.7 4.5 3.3 3.2 4.2
Cancer 0 6.5 4 0.5 6.9
Current medication, %
Statin use 0 11.6 NA 0.2 12.1
Aspirin use 1.3 12.7 NA 1.1 11.7
Blood pressure lowering 6.1 20.3 10.8 4.8 19.8
Plasma 25(OH)D (SD), nmol/L 83.7 (26.6) 55.3 (26.0) 44.3 (24.1) 83.4 (26.2) 55.3 (26.1)
CKB the China Kadoorie Biobank, CGPS the Copenhagen General Population Study, CCHS the Copenhagen City Heart Study, SD standard deviation, BMI body mass
index, SBP systolic blood pressure, DBP diastolic blood pressure
*Self-reported passivity or less than 2 h of light physical activity a week in CGPS and CCHS; MET-h/day < 8.4 (the bottom quintile) in CKB
A total of 3397 individuals in the genetic study in CKB had plasma 25(OH)D concentrations measured
25(OH)D: 1 ng/ml = 2.496 nmol/L
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lower risk of CVD (multivariable adjusted HR, 0.90 [95%
CI, 0.88,0.93]), 12% lower risk of myocardial infarction
(HR, 0.88 [95% CI, 0.84,0.93]), 7% lower risk of stroke (HR,
0.93 [95% CI, 0.90,0.98]), 7% lower risk of ischaemic stroke
(HR, 0.93 [95% CI, 0.88,0.98]), and 10% lower risk of ischae-
mic heart disease (HR, 0.90 [95% CI, 0.86,0.93]), but not
with intracerebral haemorrhage (HR, 1.05 [95% CI, 0.90,
1.19]) (Table 2). Individuals in the top quintile of plasma
25(OH)D concentrations had a 21% lower risk of incident
CVD (HR, 0.79 [95% CI, 0.73, 0.86) compared with those
in the bottom quintile. For specific types of CVD, the
adjusted HR for the top vs bottom quintile of plasma
25(OH)D concentrations were HR 0.74 [95% CI, 0.65,0.85]
for myocardial infarction and HR 0.77 [95% CI, 0.70,0.84]
for ischaemic heart disease (Table 2). In addition, a 25
nmol/L higher plasma 25(OH)D concentration was associ-
ated with all-cause and cause-specific mortality. The multi-
variable adjusted HR was 0.90 (0.88,0.93) for all-cause
mortality, 0.90 (0.86,0.93) for cardiovascular mortality, 0.86
(0.78,0.98) for mortality from myocardial infarction, 0.88
(0.82,0.95) for mortality from ischaemic heart disease, 0.93
(0.88,0.98 for cancer mortality, 0.86 (0.80,0.93) for respira-
tory disease mortality, and 0.86 (0.82,0.90) for other
mortality (Table 3).
Genetic associations with plasma 25(OH)D and risk factors
In CKB, plasma 25(OH)D concentrations per each in-
creasing allele were 1.49 nmol/L (SE 0.38, F-statistic = 89)
higher for rs12785878 (DHCR7), 0.34 nmol/L (SE 0.15, F-
statistic = 97) higher for rs10741657 (CYP2R1), 5.10 nmol/
L (SE 0.41, F-statistic = 89) higher for rs2282679 (GC/
DBP), 0.95 nmol/L (SE 0.27, F-statistic = 278.53) higher
for two-SNP score (rs12785878 + rs10741657), and 1.84
nmol/L (SE 0.21, F-statistic = 69) higher for four-SNP
score (Fig. 1 and Additional file 1: Table S1). In CGPS,
genetic variants and genetic score were also significantly
associated with plasma 25(OH)D concentrations (Fig. 1
and Additional file 1: Table S1). None of the SNPs was
associated with differences in confounders such as age,
gender, season, region, smoking, drinking, physical activ-
ity, blood pressure, and BMI in CKB or in CGPS
(Additional file 1: Tables S2 & S3).
Causal associations with cause-specific vascular disease or
mortality
In both CKB and CGPS, there was no significant genetic
association of the DHCR7/CYP2R1 risk score with
cause-specific vascular disease (Additional file 1: Tables
S4 and S5) or mortality (Additional file 1: Table S6 and S7)
Table 2 Observational association of 25(OH)D with risk of vascular diseases in CKB, CGPS, and CCHS
Diseases Continuous 25(OH)D per 25 nmol/L 25(OH)D quartiles (nmol/L) P for
trendNo. of all
events
HR (95% CI) Quartile 1 Quartile 2 Quartile 3 Quartile 4
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
CKB
Major vascular event 3868 1.02(0.98,1.07) 1.00 1.00(0.89,1.12) 1.08(0.95,1.22) 1.03(0.90,1.18) 0.344
Major coronary event 1024 0.98(0.89,1.07) 1.00 0.89(0.71,1.13) 0.99(0.78,1.27) 0.85(0.66,1.12) 0.614
Myocardial infarction 662 0.99(0.89,1.12) 1.00 0.94(0.69,1.27) 1.05(0.77,1.43) 0.99(0.71,1.38) 0.925
Stroke 2982 1.04(0.99,1.10) 1.00 1.01(0.89,1.15) 1.08(0.94,1.24) 1.08(0.93,1.26) 0.154
Ischaemic stroke 1776 0.99(0.93,1.07) 1.00 0.95(0.81,1.11) 1.04(0.88,1.23) 0.96(0.79,1.16) 0.882
Intracerebral haemorrhage 1308 1.09(1.01,1.18) 1.00 1.04(0.84,1.29) 1.08(0.86,1.35) 1.19(0.93,1.51) 0.029
Subarachnoid haemorrhage 56 1.24(0.83,1.85) 1.00 1.05(0.37,2.97) 0.42(0.10,1.72) 1.38(0.42,4.54) 0.291
Ischaemic heart disease 1024 0.98(0.89,1.07) 1.00 0.90(0.71,1.15) 1.04(0.81,1.32) 0.84(0.64,1.10) 0.596
CGPS and CCHS
Cardiovascular disease 12,110 0.90(0.88,0.93) 1.00 0.92(0.86,0.98) 0.85(0.79,0.91) 0.79(0.73,0.86) 1.3 × 10−9
Myocardial infarction 4316 0.88(0.84,0.93) 1.00 0.86(0.77,0.96) 0.81(0.72,0.91) 0.74(0.65,0.85) 5.8 × 10−10
Stroke 4490 0.93(0.90,0.98) 1.00 0.97(0.87,1.08) 0.87(0.77,0.98) 0.89(0.78,1.02) 0.022
Ischaemic stroke 3766 0.93(0.88,0.98) 1.00 0.98(0.87,1.11) 0.84(0.73,0.96) 0.90(0.78,1.04) 0.028
Intracerebral haemorrhage 542 1.05(0.90,1.19) 1.00 0.96(0.69,1.33) 1.14(0.82,1.61) 0.96(0.65,1.41) 0.87
Ischaemic heart disease 9362 0.90(0.86,0.93) 1.00 0.91(0.84,0.98) 0.86(0.79,0.93) 0.77(0.70,0.84) 1.4 × 10−11
Multivariable cox proportional hazard regression models were used to examine the association between quartile groups of 25(OH)D concentrations and risk of
vascular diseases
All values are adjusted for age (years), sex (male or female), smoking status (current smoker), alcohol intake (current drinker), season, region, SBP, and physical
activity (low activity) in CKB
All values are adjusted for age (years), sex (male or female), latitude, season, SBP, physical activity (METs, h/day), smoking status (never smoker, occasional smoker,
former smoker, or regular smoker), and alcohol intake (non-drinker, occasional drinker, former drinker, or regular drinker) in CGPS and CCHS
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after Bonferroni correction. Instrumental variable analysis
did not show any significant causal association of genetic-
ally predicted 25(OH)D with any cause-specific vascular
disease in CKB and CGPS (Fig. 2). Furthermore, genetically
predicted 25(OH)D was not significantly associated with
cause-specific mortality in CKB and CGPS (Fig. 3).
However, the instrumental variable analysis indicated a
marginal association for all-cause mortality per a 25 nmol/
L higher in genetically predicted 25(OH)D concentrations
(0.98 [0.96,1.00]) (Fig. 3). Sensitivity analyses yielded similar
findings for genetically instrumented differences in
25(OH)D concentrations using the individual SNP or four-
SNP score for each disease (Additional file 1: Table
S4 to S7).
In addition, instrumental variable analyses showed
significant associations with total and LDL cholesterol in
CKB (Fig. 4 and Additional file 1: Table S8). Each 25
nmol/l genetic increase in 25(OH)D concentrations was
associated with 0.058 mmol/L (0.22 mg/dL) and 0.034
mmol/L (0.13 mg/dL) lower total and LDL cholesterol in
Table 3 Observational association of 25(OH)D with risk of mortality in the CKB, CGPS, and CCHS
Mortality Continuous 25(OH)D per 25 nmol/L 25(OH)D quartiles (nmol/L) P for
trendNo. of all
events
HR (95% CI) Quartile 1 Quartile 2 Quartile 3 Quartile 4
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
CKB
All-cause mortality 3868 1.02(0.97,1.06) 1.00 0.95(0.84,1.07) 0.97(0.85,1.10) 0.95(0.83,1.09) 0.458
Vascular death outcomes
Major vascular event 3048 1.04(0.99,1.09) 1.00 0.93(0.81,1.07) 0.97(0.84,1.12) 1.00(0.86,1.17) 0.158
Major coronary event 1262 1.05(0.97,1.14) 1.00 0.95(0.77,1.18) 0.98(0.79,1.23) 1.13(0.89,1.42) 0.186
Myocardial infarction 898 1.04(0.94,1.14) 1.00 0.90(0.70,1.16) 1.02(0.79,1.33) 1.02(0.77,1.36) 0.427
Stroke 1590 1.06(0.98,1.13) 1.00 0.95(0.78,1.14) 1.01(0.82,1.23) 1.01(0.82,1.26) 0.136
Ischaemic stroke 118 1.06(0.84,1.33) 1.00 0.58(0.30,1.12) 0.61(0.30,1.21) 0.84(0.42,1.67) 0.622
Intracerebral haemorrhage 1416 1.05(0.98,1.14) 1.00 0.97(0.80,1.19) 1.06(0.85,1.32) 1.04(0.82,1.31) 0.166
Subarachnoid haemorrhage 68 1.01(0.98,1.03) 1.00 0.95(0.18,4.93) 1.52(0.32,7.33) 1.10(0.18,6.83) 0.685
Ischaemic heart disease 1262 1.05(0.97,1.14) 1.00 0.95(0.77,1.18) 0.98(0.79,1.23) 1.13(0.89,1.42) 0.186
Non-vascular death outcomes
Cancer 370 1.00(0.99,1.01) 1.00 1.22(0.81,1.83) 1.17(0.76,1.79) 1.00(0.63,1.58) 0.818
Respiratory diseases 46 1.00(0.99,1.01) 1.00 0.91(0.47,1.73) 1.28(0.68,2.42) 0.75(0.35,1.60) 0.798
Infections 64 1.00(0.98,1.02) 1.00 0.51(0.08,3.17) 0.38(0.06,2.53) 1.00(0.21,4.81) 0.946
CGPS and CCHS
All-cause mortality 10,845 0.90(0.88,0.93) 1.00 0.81(0.77,0.85) 0.79(0.75,0.83) 0.77(0.73,0.82) 2 × 10−20
Vascular death outcomes
Cardiovascular disease 3303 0.90(0.86,0.93) 1.00 0.85(0.78,0.93) 0.78(0.71,0.87) 0.80(0.72,0.90) 1.9 × 10−8
Myocardial infarction 676 0.86(0.78,0.98) 1.00 0.68(0.55,0.83) 0.78(0.63,0.97) 0.70(0.54,0.90) 0.0037
Stroke 743 0.93(0.86,1.03) 1.00 0.97(0.81,1.17) 0.74(0.60,0.92) 1.00(0.79,1.26) 0.28
Ischaemic stroke 385 0.88(0.78,1.00) 1.00 1.06(0.82,1.36) 0.65(0.48,0.89) 0.96(0.69,1.34) 0.18
Intracerebral haemorrhage 178 1.05(0.88,1.25) 1.00 1.06(0.71,1.57) 0.96(0.62,1.49) 1.16(0.72,1.86) 0.71
Ischaemic heart disease 1395 0.88(0.82,0.95) 1.00 0.80(0.70,0.92) 0.80(0.69,0.93) 0.76(0.63,0.90) 6 × 10−4
Non-vascular death outcomes
Cancer 3127 0.93(0.88,0.98) 1.00 0.86(0.78,0.94) 0.87(0.78,0.96) 0.79(0.71,0.89) 9.7 × 10−5
Respiratory diseases 1065 0.86(0.80,0.93) 1.00 0.69(0.59,0.82) 0.67(0.56,0.80) 0.71(0.59,0.87) 6.6 × 10−4
Infections 430 0.84(0.76,0.95) 1.00 0.76(0.59,0.98) 0.85(0.66,1.11) 0.73(0.53,1.00) 0.082
All other causes 2463 0.86(0.82,0.90) 1.00 0.73(0.66,0.81) 0.71(0.63,0.79) 0.68(0.59,0.78) 4.6 × 10−10
Multivariable cox proportional hazard regression models were used to examine the association between quartile groups of 25(OH)D concentrations and risk
of mortality
All values are adjusted for age (years), sex (male or female), smoking status (current smoker), alcohol intake (current drinker), season, region, SBP, and physical
activity (low activity) in CKB
All values are adjusted for age (years), sex (male or female), latitude, season, SBP, physical activity (METs, h/day), smoking status (never smoker, occasional smoker,
former smoker, or regular smoker), and alcohol intake (non-drinker, occasional drinker, former drinker, or regular drinker) in CGPS and CCHS
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CKB. However, we did not observe causal associations
for lipids and lipoproteins in CGPS and pooled cohorts
(Fig. 4 and Additional file 1: Table S9).
Discussion
The novel findings of this MR study involving 99,012
Chinese adults and 106,911 European adults suggest that
genetically higher plasma 25(OH)D levels were not asso-
ciated with lower risk of cause-specific vascular disease
such as myocardial infarction, ischaemic heart disease,
ischaemic stroke, stroke, intracerebral haemorrhage, and
subarachnoid haemorrhage among both Chinese and
European adults. Likewise, 25(OH)D may not influence
lipid levels. Our results suggest that the inverse associa-
tions of vitamin D with cause-specific vascular disease
and lipids could be the results of confounding.
Using an MR approach free from confounding and
reverse causation, our study for the first time showed
that genetically predicted 25(OH)D was not associated
with intracerebral haemorrhage, subarachnoid haemor-
rhage, stroke, and ischaemic stroke, thus suggesting that
vitamin D may not play a causal role in development of
cause-specific vascular disease in Chinese or Europeans.
The results suggest that individuals should be cautious
about long-term supplementation with high doses of
Table 4 Observational association of 25(OH)D with lipids in CKB, CGPS, and CCHS
Lipids Continuous 25(OH)D per 25 nmol/L 25(OH)D quartiles (nmol/L) P for
trendBeta ± SE Quartile 1 Quartile 2 Quartile 3 Quartile 4
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
CKB (n = 17,755)
Apoa, mg/dL 1.52 ± 0.21 127.90 ± 0.43 129.48 ± 0.42 129.79 ± 0.41 130.73 ± 0.45 < 0.0001
Apob, mg/dL 0.04 ± 0.00 84.52 ± 0.46 85.95 ± 0.45 84.14 ± 0.44 81.42 ± 0.44 < 0.0001
Lpa, mmol/L 0.01 ± 0.49 37.94 ± 1.00 36.40 ± 0.99 35.17 ± 0.96 37.15 ± 1.02 0.984
TC, mmol/L −0.05 ± 0.01 4.65 ± 0.02 4.74 ± 0.02 4.66 ± 0.02 4.53 ± 0.02 < 0.0001
HDL, mmol/L 0.03 ± 0.01 1.20 ± 0.01 1.22 ± 0.01 1.23 ± 0.01 1.26 ± 0.01 < 0.0001
LDL, mmol/L −0.03 ± 0.01 2.32 ± 0.01 2.38 ± 0.01 2.34 ± 0.01 2.28 ± 0.02 < 0.0001
TG, mmol/L −0.16 ± 0.02 2.18 ± 0.04 2.09 ± 0.03 2.03 ± 0.03 1.75 ± 0.03 < 0.0001
CGPS and CCHS (n = 106,911)
Apoa, mg/dL* 0.01 ± 0.002 160.63 ± 31.08 161.78 ± 29.96 163.35 ± 30.09 164.39 ± 32.33 < 0.0001
Apob, mg/dL* −0.08 ± 0.002 125.27 ± 40.06 118.58 ± 35.59 112.93 ± 33.17 104.34 ± 29.31 < 0.0001
Lpa, mg/dL* 0.32 ± 0.231 22.99 ± 31.53 22.80 ± 30.25 22.83 ± 32.66 23.90 ± 31.30 0.15
TC, mmol/L −0.14 ± 0.006 5.85 ± 1.16 5.80 ± 1.12 5.71 ± 1.10 5.53 ± 1.09 < 0.0001
HDL, mmol/L 0.06 ± 0.003 1.38 ± 0.50 1.46 ± 0.51 1.51 ± 0.51 1.56 ± 0.52 < 0.0001
LDL, mmol/L* −0.15 ± 0.006 3.44 ± 1.00 3.36 ± 0.96 3.27 ± 0.95 3.09 ± 0.91 < 0.0001
TG, mmol/L* −0.26 ± 0.007 2.08 ± 1.49 1.78 ± 1.10 1.60 ± 0.95 1.39 ± 0.77 < 0.0001
Linear regression was also used to assess the associations of 25(OH)D with lipids
All values are adjusted for age (years), sex (male or female), smoking status (current smoker), alcohol intake (current drinker), season, SBP, and physical activity
(low activity) in CKB
All values are adjusted for age (years), sex (male or female), latitude, season, region, SBP, physical activity (METs, h/day), smoking status (never smoker, occasional
smoker, former smoker, or regular smoker), and alcohol intake (non-drinker, occasional drinker, former drinker, or regular drinker) in CGPS and CCHS
*Data only available in CGPS
Fig. 1 Genetic association with 25(OH)D (nmol/L) in CKB and CGPS.
Data are presented as beta ± SE. Linear regression was used to
assess the per allele effect of each SNP or genetic score on plasma
25(OH)D concentrations. All values are adjusted for age, sex, and
season and stratified by region. CKB, the China Kadoorie Biobank;
CGPS, the Copenhagen General Population Study
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vitamin D3 [10]. The results are consistent with recent
MR studies which did not show a causal effect of circu-
lating vitamin D levels on risk of ischaemic heart disease
or myocardial infarction [12], or cardiovascular mortality
[13]. Findings from RCTs that do not show a protective
effect of vitamin D3 supplementation on cardiovascular
outcomes [9–11], supported our findings. However,
previous RCTs did not specifically focus on vitamin D-
deficient population. Thus, available evidence is not
enough to support cardiovascular benefits or hazards of
the commonly used vitamin D doses, but whether higher
doses of vitamin D are beneficial is uncertain, or whether
vitamin D supplementation has vascular effects in individ-
uals with vitamin D deficiency remains unclear [9]. It
worth noting that there are two major forms of vitamin D:
vitamin D2 (ergocalciferol) and vitamin D3 (cholecalcif-
erol). A meta-analysis demonstrated that vitamin D3 is
more effective than vitamin D2 in maintaining circulating
concentrations of 25(OH)D [28]. Previous randomised
double-blind placebo-controlled trial examining the
effects of vitamin D2 or D3 supplementation on cardio-
metabolic risk showed that both vitamin D2 or D3 did not
influence blood pressure and cardiovascular risk, but de-
creased ApoB concentration and pulse wave velocity. Only
vitamin D2 decreased total cholesterol [29]. However, so
far, no RCT has investigated the benefits of supplemental
vitamin D2 or D3 in preventing vascular diseases in Chin-
ese adults. Whether vitamin D2 or D3 supplementation
will be beneficial in patients with CVD or high-risk older
patients is unknown and warrants further investigation.
Our findings could be explained by previous evidence
that low 25(OH)D concentration is a marker of an
unhealthy lifestyle or poor health [30], which has been as-
sociated with increased risk of vascular disease. Further-
more, previous MR studies suggest that cardiovascular
factors [31], such as high remnant cholesterol, LDL choles-
terol [32], and obesity [33], decrease plasma concentrations
of 25(OH)D and increase vascular risk. That means low
Fig. 2 Instrumental variable estimates for vascular diseases. Analyses of two-SNP score with vascular diseases were estimated using cox
proportional hazard regression models. We used a two-SNP score as instrument to estimate the influence of a 25 nmol/L increase in 25(OH)D
concentrations on risk of vascular diseases. We calculated instrumental variable estimates of genetically determined hazard ratios by using the
Wald-type estimator, which involves taking the ratio of the gene-outcome log hazard ratios to the gene-exposure coefficient and then
exponentiating to express it as a hazard ratio. Two-SNP score was calculated based on DHCR7 + CYP2R1: rs12785878 + rs10741657 in CKB and
DHCR7 + CYP2R1: rs7944926 + rs10741657 in CGPS. The r2 between rs12785878 and rs7944926 is 0.87. All values are adjusted for age, sex, and
season and stratified by region
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plasma 25(OH)D is a consequence of CVD rather than a
causal factor. This could explain why we did not observe a
causal association in MR analyses, despite strong observa-
tional associations in Europeans [4, 5]. In addition, a
previous study showed that elevated parathyroid hormone
levels identify a population with higher cardiovascular risk.
Parathyroid hormone correlates to cardiovascular risk, but
not vitamin D [34]. The potential mechanism is that para-
thyroid hormone induces oxidative stress and affects
endothelial function [35]. Therefore, we have to acknow-
ledge that the vitamin D-dependent parathyroid hormone,
rather than vitamin D itself, might be a better predictor of
cardiovascular risk. However, we have to acknowledge that
the possibility of a non-linear association of vitamin D
with cardiovascular outcomes cannot be excluded as it
was not tested in the present MR study.
Although our MR analysis did not show causal effects of
25(OH)D on all-cause and cause-specific mortality in
Chinese, results from Europeans demonstrated that
25(OH)D might be causally related to all-cause mortality
and cancer mortality. Our findings are consistent with a
European MR study, which showed that genetically
reduced vitamin D concentrations were associated with
increased all-cause, cancer mortality, but not with cardio-
vascular mortality [13]. Our results in Europeans are also
supported by a meta-analysis of 56 RCTs mainly conducted
in Europeans, which showed that vitamin D decreased all-
cause and cancer mortality [11]. However, when different
forms of vitamin D were assessed, only vitamin D3 (chole-
calciferol) decreased mortality. Vitamin D2 (ergocalciferol)
may even increase mortality [11]. It should be noted that
recent European MR studies found evidence that genetic-
ally determined vitamin D concentrations were inversely
associated with type 2 diabetes [36], and blood pressure
and risk of hypertension [37]. These results could at least
partly explain the reduced mortality among Europeans
observed by us. However, so far, neither RCTs nor MR
studies have investigated the causal effect of vitamin D on
all-cause and cause-specific mortality in Chinese adults.
Our present MR analysis for the first time documented
Fig. 3 Instrumental variable estimates for mortality. Analyses of two-SNP score with mortality were estimated using cox proportional hazard
regression models. We used a two-SNP score as instrument to estimate the influence of a 25 nmol/L increase in 25(OH)D concentrations on
risk of mortality. We calculated instrumental variable estimates of genetically determined hazard ratios by using the Wald-type estimator, which
involves taking the ratio of the gene-outcome log hazard ratios to the gene-exposure coefficient and then exponentiating to express it as a
hazard ratio. Number of individuals in CKB and CGPS are 99,012 and 106,911, respectively. Two-SNP score was calculated based on DHCR7 +
CYP2R1: rs12785878 + rs10741657 in CKB and DHCR7 + CYP2R1: rs7944926 + rs10741657 in CGPS. The r2 between rs12785878 and rs7944926 is
0.87. All values are adjusted for age, sex, and season and stratified by region
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that genetically elevated 25(OH)D was not associated with
cause-specific vascular disease or mortality. These findings
suggest possible ethnic differences in relationships between
25(OH)D levels and cancer mortality. A previous study
showed that the effect of vitamin D3 supplementation on
advanced colorectal adenomas varied according to vitamin
D receptor genotypes [38]. Among the rs7968585AA geno-
type individuals (26%), supplemental vitamin D3 reduced
risk by 64%, but increased risk by 41% among individuals
with rs7968585 G alleles (74%) [38]. Therefore, whether
benefits from vitamin D supplementation for the preven-
tion of cancer vary according to vitamin D receptor geno-
type is unknown and warrants further investigation.
Previous RCTs have shown inconsistent results for the
effects of vitamin D on plasma lipid levels [39–44]. How-
ever, it is worth noting that none of the RCTs were specif-
ically conducted for evaluating the effect of supplemental
vitamin D on lipids and lipoproteins. Interestingly, the
largest trial (The WHI-Calcium+Vitamin D trial) con-
ducted in 36,282 women showed that patients receiving
combined vitamin D and omega-3 fatty acid supplementa-
tion had decreased serum very low-density lipoprotein
cholesterol and serum triglycerides [42] while 400 IU
vitamin D3 plus 1000mg elemental calcium carbonate
daily showed a decrease in LDL cholesterol after 6 weeks
of intervention [43]. Consistently, our MR analysis in
Chinese adults for the first time showed that each 25
nmol/l genetic increase in 25(OH)D concentration was as-
sociated with 0.058mmol/L(0.22mg/dL) and 0.034mmol/
L(0.13mg/dL) lower total and LDL cholesterol, thus sug-
gesting that 25(OH)D may play a causal role in lipid me-
tabolism at least in Chinese adults. However, the potential
mechanism warrants further investigation.
In the present MR analysis, we considered three assump-
tions to ensure the validity of our analyses [17, 18, 27].
First, our data demonstrated that the individual SNP and
genetic score were associated with 25(OH)D (F statistic >
15), suggesting strong instrumental variables. Second, the
instruments should be independent of measured and un-
measured confounders. Indeed, we found no association of
genetic variants or score with measured confounders, thus
satisfying an important condition for a valid MR experi-
ment. Third, the genetic score should have no pleiotropic
effect on the outcomes, which is an important consider-
ation in MR studies. The third assumption may be violated
by pleiotropy [45]. The SNPs encoding enzymes involved
in the synthesis of 25(OH)D are believed to be more
specific for 25(OH)D, but SNPs involved in the transport
of 25(OH)D may have pleiotropic effects in addition to
their effects on plasma 25(OH)D concentrations alone [31,
46, 47]. However, when we excluded SNPs involved in
the transport of 25(OH)D, the association remained
unchanged.
Several strengths of the present study merit consider-
ation. This is the first MR analysis to examine the causal
association of 25(OH)D with intracerebral haemorrhage
and subarachnoid haemorrhage. This large MR study had
a large number of disease events and high-quality
25(OH)D measurements by well-trained technicians and
an appropriate design allowed us to gain sufficient power
for estimation of causal effects. Another strength of our
study was detailed information on known confounding
factors, which allowed us to examine the three MR as-
sumptions. Finally, we used standardised analytic methods
to compare the differences in causal effects between Chin-
ese and Europeans.
Conclusion
In summary, this large-scale analysis provides reliable
evidence that higher 25(OH)D may not play a causal role
in developing cause-specific vascular disease in Chinese
or Europeans. MR analysis further demonstrated that
high vitamin D may not influence lipids.
Additional file
Additional file 1: Supplemental tables providing additional information
on genetic association with 25(OH)D, lipids and CVD. (DOCX 52 kb)
Fig. 4 Instrumental variable estimates for lipids. Linear regression was
also used to assess the associations of a two-SNP score with lipids. We
used a two-SNP score as instrument to estimate the influence of a 25
nmol/L increase in 25(OH)D concentrations on lipids. We calculated
instrumental variable estimates of genetically determined hazard ratios
by using the Wald-type estimator, which involves taking the ratio of
the gene-outcome coefficient to the gene-exposure coefficient. Two-
SNP score was calculated based on DHCR7+ CYP2R1: rs12785878 +
rs10741657 in CKB and DHCR7 + CYP2R1: rs7944926 + rs10741657 in
CGPS. The r2 between rs12785878 and rs7944926 is 0.87. All values
are adjusted for age, sex, and season and stratified by region
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